Saturday, September 26, 2026

Abridged - Capital Cycle IQ & Forensic Files on the Big 5 Hyperscalers (MSFT, AMZN, ORCL, META, GOOG)

Microsoft, Amazon, Oracle, Meta and Alphabet face another two years of record AI data-center investment amid $3 trillion in commitments, leases, guarantees and potential off-balance-sheet…

ORCL $419B

Cassandra Unchained Sep 26 9 clicks

Sep 26 HONA $49B

New Buy : Honeywell Aerospace $HONA

D Invests 13 clicks

Sep 26 VBNK $720M

VersaBank: The Bank Behind the Bank – How a Canadian Branchless Pioneer Wants to Make Asset-Backed Securities Obsolete

Substack von Philipp 5 clicks

From X

@valuedontlie Sep 26

Colin King on X

To $FOUR credit, they've already been buying back lots of stock and recently killed the Up-C structure (which are terrible) https://t.co/0kRHGBybWV https://t.co/BBTKz873dC

@Fierce__beast Sep 26

Fierce_beast on X

@brianjrobben I mention this possibility as a reason for why it sold down too. I don't think 8% returns are bad for $MCD, but yea, it's not obviously good here. At the same time i'm a bit torn given i am short many resturants this idea maybe is a bit of an idea to balance my book a bit.

@AltayCapital Sep 26 2 clicks

AltayCap on X

The only industries where obvious capital allocation lingo is useful is leasing / banking / insurance. It's much more nebulous in operating businesses that do real things. $AER ceo saying the cheapest commercial jets are on the NYSE under the ticker AER is easy to understand. As math is pencilling out cost of new orders vs buying back stock. $FOUR competes in the real world. Leasing/banking products are fungible. Much harder biz to forecast. Cap allocation is still important, but a lot harder.

@Fierce__beast Sep 26 1 click

Fierce_beast on X

@theotheraharon But i'm looking for ideas that have been specifically impacted by the degrossing event. Not sure $MXCT or $RARE are correlated to that. The idea is find stocks that are irrationally selling off or getting bid due to the degrossing, then pick your spots from the list you find.

@Fierce__beast Sep 26

Fierce_beast on X

@SolutionOrganic There are other reasons, beyond the return to buy it. But my base case is closer to 8% here. But there are reasons for instance that if inflation rise or rates increase, i think bonds would suffer more than $MCD and $otis at this valuation if you look out 1 year

@Fierce__beast Sep 26

Fierce_beast on X

I guess the issue with buying corporate debt is what if interest rates keep going up or if there is inflation? Fixed rate coupon at 6% you might need to wait till maturity to get paid back. But what if there's also increased inflation? according to blackrock it looks like weighted average maturity is like 9-10 years or so for their BBB index $LQDP. With $MCD and $OTIS i think you get a 6%+ total return in most inflation or interest rate environments at these valuations, hopefully more. I was underwriting something closer to 7-8% for both those stocks personally, but probably 6% would be OK, as I am 200% leveraged long and maybe gonna go higher, so expected return on my equity from these ideas is closer to 12%, maybe 16%. But then adds some other benefits that seem decently valuable, like MCD beta .4, otis .88, defensively better than a lot of stocks in case of a recession. Maybe $MCD is just getting degrossed as everyone leveraged it up on their portfolios at the same time expecting an accepetable return of lets say 5% but leveraged 2x or more they were getting a 10%+ ROE on thier protfolio and now degrossing it at the same time. Not totally sure if i'm underwriting correctly, or if this is the best idea in the world, seemed just OK.

@Fierce__beast Sep 26 1 click

Fierce_beast on X

@JJNews002 bought a little of it too $ABVX

@Fierce__beast Sep 26 1 click

Fierce_beast on X

What are people buying and selling in this apparent biotech degrossing phase? I am looking given the irrationality of the situation and the temporary opportunities it may present on both sides of the ledger. $XBI recent returns seem driven by two stocks $MRNA and $TWST. I shorted small size some $CDNA, $MRVI. Long $ACAD, $UTHR and $CELC. Are these completely idiotic ideas?

GitLab: Positioned To Benefit From Software Development Explosion

GitLab's Q2 FY2027 beat and raised guidance reflect large deals, paid consumption growth and AI demand, while valuation rests on revenue…

GTLB $8.2B

Research and Value Sep 26 3 clicks

Updates

FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.

FGPR $254MPRTH $642M

Nat Stewart - Stock Picking Newsletter Sep 25 12 clicks

The Enron-Era Tricks Are Back in AI: How These Companies Are Hiding Their Debt | The Weekly Wrap

Steve Eisman says AI companies are reviving Enron-era off-balance-sheet and circular financing, alongside concerns around Oracle and Blue…

ORCL $419B

Steve Eisman Sep 25 5 clicks

Reddit: DCF Valuation

Reddit’s DCF values shares at $225, driven by international ARPU expansion from $2.2 to $8.3 by 2035 and 38% operating margins.

RDDT $28B

Hated Moats Sep 25 7 clicks

Oklo: Shares Have Plunged, But I'm Still Bearish

Oklo shares have fallen 77% since October 2025 as commercialization slips beyond 2027, revenue estimates fall and dilution continues.

OKLO $6.7B

Ian Bezek Sep 25 5 clicks

TSOH Weekly Roundup (09/25/2026)

TSOH Weekly Roundup covers Ralph Lauren’s $1 billion distribution pullback, Peloton’s $2,195 foldable treadmill and $800 million…

RL $21BPTON $2.2B

TSOH Investment Research Sep 25 5 clicks

IonQ: Nvidia QPU Catalyst Isn't Enough

IonQ's Q2 2026 revenue rose 287% to $80.1 million, but durability hinges on its $485 million RPO and enterprise adoption for production AI…

IONQ $18B

Deep Value Investing Sep 25 2 clicks

Single Stock Spotlight #15: Rocket Companies (RKT)

Rocket Companies combines Redfin, Rocket Mortgage and Mr. Cooper into an end-to-end homeownership platform, adding mortgage servicing fees…

RKT $33B

Hidden Rock Capital's Newsletter Sep 25 6 clicks

Eckert & Ziegler: The Pick-and-Shovel Supplier of the Radiopharma Boom – Finally at a Fair Price

Eckert & Ziegler trades near €12, about 14 times expected earnings, as its isotope supply business expands with radiopharma demand despite…

NVS $271B

Substack von Philipp Sep 25 3 clicks

(Public) Mach Natural Resources - A Buying Opportunity

Mach Natural Resources' Q2 distributable cash fell to $60.1 million as development spending rose, prompting a distribution cut; its units…

MNR $1.7B

HFI Research Sep 25 4 clicks

CNH · long

Cnh Industrial NV

CNH Industrial, the No. 2 global agricultural-equipment OEM, is pitched long at about $10 per share.

CNH $16B

Value Investors Club May 31 1 click

Tidewater (TDW): a first-pass look

Tidewater’s $22,600 average day rate and $598 million FY2025 EBITDA rest on an aging OSV fleet, scant newbuilds and fleet acquisitions…

TDW $4B

Stock Thoughts Jun 27

The Biggest Bull Signal On Entravision

Entravision’s lost Meta relationship reset its business model, setting up a bullish case for the company’s recovery.

EVC $682M

The Value Road Jun 26 5 clicks

SAP: DCF Valuation

SAP’s DCF valuation sets a $260 base-case target versus a $155.09 ADR price, based on cloud migration, AI efficiencies and expanding EBIT…

SAP $241B

Hated Moats Jun 26

Duffy’s Last Dance

CME CEO Terry Duffy moves to executive chairman while suing the CFTC over Kalshi’s approval to list perpetual futures, defending CME’s…

CME $95B

Net Interest Jun 26

New Buy : Zoetis 🐕

Zoetis trades near 10x EV/EBIT after its selloff, with animal-health leadership, a $9.5 billion revenue base and companion-animal demand…

ZTS $29B

D Invests Jun 26

Adobe Business History

Adobe built PostScript, Photoshop and PDF into desktop-publishing standards, using free Acrobat Reader and integrated Creative Suite tools…

ADBE $92B

Speedwell Memos Jun 25 1 click

Intuit Investment Case Summary

Intuit’s investment case is condensed into a one-page company overview.

INTU $75B

Global Outperformers Jun 25

Deep Dive: XPEL

XPEL sells paint-protection film and DAP cutting software, using 90,000-plus vehicle templates to win share from 3M and Eastman.

XPEL $1.2B

Rebound Capital Jun 24 1 click

I Didn't Know Then. I Know Now. — ISRG & PME.AX

Intuitive Surgical and Pro Medicus are new medical-technology positions, with robotic-assisted surgery cited as cutting femur hospital…

ISRG $144B

Sleep Well Investments Jun 24

Saturday, September 26, 2026

Colin King on X

Fierce_beast on X

AltayCap on X

Fierce_beast on X

Fierce_beast on X

Fierce_beast on X

Fierce_beast on X

Fierce_beast on X

Investor Letters

Publications we follow

Newsletters 93

YouTube 4

Blogs 12

Seeking Alpha 42 of 206

X accounts we follow

Investor letters we follow

Sectors